Citius Oncology, Inc. financial data

Symbol
CTOR on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Commerce Drive, 1 St Floor, Cranford, NJ
State of incorporation
Cayman Islands
Fiscal year end
September 30
Former names
TenX Keane Acquisition (to 8/5/2024)
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 34.4 % -4.55%
Return On Equity -113 % -309%
Return On Assets -33.9 % -556%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.6M shares
Common Stock, Shares, Outstanding 71.6M shares +2956%
Entity Public Float 47.7T USD
Common Stock, Value, Issued 7.16K USD +4184%
Weighted Average Number of Shares Outstanding, Basic 71.6M shares +6%
Weighted Average Number of Shares Outstanding, Diluted 71.6M shares +6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.26M USD +10.1%
General and Administrative Expense 9.95M USD +335%
Operating Income (Loss) -1.32M USD -92.4%
Nonoperating Income (Expense) 3.25M USD -22%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.39M USD -39.5%
Income Tax Expense (Benefit) 264K USD +83.5%
Net Income (Loss) Attributable to Parent -23.1M USD -591%
Earnings Per Share, Basic -0.33 USD/shares -467%
Earnings Per Share, Diluted -0.33 USD/shares -467%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 14.4M USD
Assets, Current 17.1M USD +29250%
Assets 90.5M USD +24.6%
Accounts Payable, Current 5.87M USD
Accrued Liabilities, Current 6.23M USD +1557%
Liabilities, Current 43.4M USD +2021%
Deferred Income Tax Liabilities, Net 1.99M USD
Liabilities 49.2M USD
Retained Earnings (Accumulated Deficit) -45.9M USD -2211%
Stockholders' Equity Attributable to Parent 41.3M USD +81.7%
Liabilities and Equity 90.5M USD +24.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -192K USD -13.6%
Net Cash Provided by (Used in) Financing Activities -24.5M USD
Net Cash Provided by (Used in) Investing Activities 24.7M USD
Common Stock, Shares Authorized 100M shares -33.3%
Common Stock, Shares, Issued 71.6M shares +2956%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 584 USD
Deferred Tax Assets, Valuation Allowance 4.93M USD +21.9%
Deferred Income Tax Expense (Benefit) 264K USD +83.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.53M USD +62.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +900%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 87.2M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.81M USD -5.66%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%